Alcon
About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Employees: 25,599
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
17% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 70
4.13% more ownership
Funds ownership: 48.94% [Q3] → 53.07% (+4.13%) [Q4]
0% less funds holding
Funds holding: 646 [Q3] → 643 (-3) [Q4]
8% less capital invested
Capital invested by funds: $24.1B [Q3] → $22.2B (-$1.92B) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 229
20% less call options, than puts
Call options by funds: $164M | Put options by funds: $205M
29% less funds holding in top 10
Funds holding in top 10: 17 [Q3] → 12 (-5) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Keybanc Brett Fishbin 29% 1-year accuracy 5 / 17 met price target | 15%upside $112 | Overweight Maintained | 31 Mar 2025 |
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 23%upside $120 | Outperform Maintained | 28 Mar 2025 |
Needham David Saxon 40% 1-year accuracy 26 / 65 met price target | 13%upside $110 | Buy Maintained | 28 Mar 2025 |
Baird Jeff Johnson 37% 1-year accuracy 10 / 27 met price target | 11%upside $108 | Outperform Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 5 articles about ALC published over the past 30 days
